{
    "hands_on_practices": [
        {
            "introduction": "In clinical practice, diagnosing excoriation (skin-picking) disorder hinges on its characteristic behavioral patterns, yet a common step is to perform a skin biopsy to rule out other primary dermatoses. Often, these biopsies return with non-specific findings, creating a potential diagnostic dilemma. This exercise guides you through a quantitative method to resolve this apparent conflict, using Bayesian principles to demonstrate how a test with low diagnostic power does not necessarily weaken a strong, behaviorally-anchored clinical diagnosis . Mastering this approach is crucial for confidently prioritizing behavioral diagnostic criteria, which is a cornerstone of managing psychodermatologic conditions.",
            "id": "4489454",
            "problem": "A patient presents with recurrent excoriations where non-specific histology complicates diagnostic certainty, but behavioral history strongly supports excoriation disorder. Consider the following scenario. A $32$-year-old woman has had $12$ months of recurrent excoriations on the face and extensor forearms. She reports an irresistible urge to pick preceded by tension and followed by relief, repeated unsuccessful attempts to stop, and clinically significant distress with impaired social functioning. There is no mucosal involvement. Examination shows crusted erosions of varying age in easily reachable areas, with relative sparing of the mid-back. A punch biopsy from an excoriated site shows an ulcer with granulation tissue and a mixed inflammatory infiltrate without vasculitis; special stains are negative for organisms; and perilesional direct immunofluorescence is negative for immune complex deposition. Assume that the clinical interview confirms criteria for excoriation (skin-picking) disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5): recurrent skin picking resulting in skin lesions, repeated attempts to stop, clinically significant distress or impairment, the disturbance is not attributable to the physiologic effects of a substance or another medical condition, and is not better explained by symptoms of another mental disorder.\n\nFrom first principles, use core definitions and evidence synthesis to reconcile the conflicting signals of behaviorally anchored diagnosis and non-specific histology. As a foundation, take the following well-tested facts:\n\n- Excoriation disorder is classified under Obsessive-Compulsive and Related Disorders in DSM-5 and is diagnosed behaviorally by meeting the above criteria.\n- When histopathology samples an excoriated site, the most common pattern is non-specific ulceration and secondary changes, which has little discriminatory power between self-induced lesions and many dermatologic conditions.\n- Bayesian evidence synthesis is governed by Bayes’ theorem, which in odds form can be written as $$\\text{posterior odds} = \\text{prior odds} \\times \\text{likelihood ratio}.$$ With prior odds $$\\text{prior odds} = \\frac{P(\\text{condition})}{1 - P(\\text{condition})}.$$ For a binary test, $$\\text{LR}^+ = \\frac{\\text{sensitivity}}{1 - \\text{specificity}}, \\quad \\text{LR}^- = \\frac{1 - \\text{sensitivity}}{\\text{specificity}}.$$\n\nIn this clinic population, suppose the pretest probability based on DSM-5 criteria and phenomenology is $$P(\\text{excoriation disorder}) = 0.70.$$ Assume, consistent with published clinicopathologic series, that the finding of “non-specific ulceration” at an excoriated site has a sensitivity $$\\text{sensitivity} = 0.80$$ and specificity $$\\text{specificity} = 0.20$$ for excoriation disorder when contrasted with a heterogeneous set of alternative dermatologic diagnoses. Consider the histology result “non-specific ulceration” as a positive test for excoriation disorder. Use these quantities to compute the posterior probability $$P(\\text{excoriation disorder} \\mid \\text{non-specific histology}).$$ Then, integrating DSM-5’s behavioral definition and the evidence synthesis, select the single best next-step management strategy among the options.\n\nWhich of the following is the most appropriate next step?\n\nA. Initiate Cognitive Behavioral Therapy (CBT) with Habit Reversal Training (HRT), provide psychoeducation, stimulus control, and simple wound care; coordinate collaborative care with mental health; defer immunosuppression and antibiotics absent signs of infection.\n\nB. Escalate to systemic corticosteroids for presumed autoimmune blistering disease to reduce excoriations while arranging repeat biopsies.\n\nC. Perform repeat biopsies from the edge of new lesions and treat empirically with doxycycline; postpone any behavioral intervention until histology is definitive.\n\nD. Start high-dose isotretinoin for presumed acne excoriée and avoid psychiatric referral to prevent reinforcement of picking behavior.\n\nE. Initiate N-acetylcysteine (NAC) and a Selective Serotonin Reuptake Inhibitor (SSRI) without psychotherapy; treat excoriations with topical corticosteroids because pharmacotherapy alone has the strongest evidence base.",
            "solution": "The user wants me to solve a clinical reasoning problem by first validating the problem statement, then performing a Bayesian calculation, and finally selecting the most appropriate management strategy.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n-   **Patient Profile:** A $32$-year-old woman.\n-   **Clinical History:** $12$ months of recurrent excoriations on the face and extensor forearms. The patient reports an irresistible urge to pick preceded by tension and followed by relief, repeated unsuccessful attempts to stop, and clinically significant distress with impaired social functioning. No mucosal involvement.\n-   **Physical Examination:** Crusted erosions of varying age in easily reachable areas, with relative sparing of the mid-back.\n-   **Histopathology:** A punch biopsy from an excoriated site shows an ulcer with granulation tissue and a mixed inflammatory infiltrate without vasculitis.\n-   **Ancillary Tests:** Special stains are negative for organisms; perilesional direct immunofluorescence is negative for immune complex deposition.\n-   **Diagnostic Assumption:** The clinical interview confirms criteria for excoriation (skin-picking) disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).\n-   **Fact 1:** Excoriation disorder is classified under Obsessive-Compulsive and Related Disorders in DSM-5 and is diagnosed behaviorally.\n-   **Fact 2:** Histopathology of an excoriated site commonly shows non-specific ulceration and secondary changes.\n-   **Fact 3 (Bayesian Framework):**\n    -   $\\text{posterior odds} = \\text{prior odds} \\times \\text{likelihood ratio}$\n    -   $\\text{prior odds} = \\frac{P(\\text{condition})}{1 - P(\\text{condition})}$\n    -   $LR^+ = \\frac{\\text{sensitivity}}{1 - \\text{specificity}}$\n    -   $LR^- = \\frac{1 - \\text{sensitivity}}{\\text{specificity}}$\n-   **Quantitative Data:**\n    -   Pretest probability: $P(\\text{excoriation disorder}) = 0.70$.\n    -   Sensitivity of \"non-specific ulceration\" for excoriation disorder: $\\text{sensitivity} = 0.80$.\n    -   Specificity of \"non-specific ulceration\" for excoriation disorder: $\\text{specificity} = 0.20$.\n-   **Instruction:** Consider the histology result \"non-specific ulceration\" as a positive test for excoriation disorder.\n\n**Step 2: Validate Using Extracted Givens**\n\n-   **Scientific Grounding:** The problem is scientifically sound. It presents a classic clinical scenario of excoriation disorder, consistent with DSM-5 criteria. The histopathology findings are typical for a mechanically induced lesion and the negative ancillary tests correctly rule out common mimics like infectious or autoimmune bullous diseases. The application of Bayes' theorem is a standard and appropriate method for updating diagnostic probability based on test results in clinical epidemiology. The given sensitivity and specificity values, while hypothetical, are plausible for a test with low discriminatory power, which is the central point of the problem. A test with low specificity ($0.20$) means it has a high false positive rate ($1 - \\text{specificity} = 0.80$), correctly modeling that \"non-specific ulceration\" is common in many conditions other than excoriation disorder.\n-   **Well-Posed:** The problem is well-posed. It provides all necessary data and definitions to perform the requested calculation. The question asks for the \"most appropriate next step,\" which is a standard format in clinical reasoning problems that require integrating quantitative data with established standards of care.\n-   **Objective:** The problem is stated in objective, clinical language. It is free from bias, subjectivity, or speculative claims.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is scientifically grounded, well-posed, objective, and internally consistent. It is a valid problem. I will proceed with the solution.\n\n### Solution Derivation\n\nThe core task is to determine how the \"non-specific\" biopsy result should influence the clinical management. This requires two steps: first, quantitatively assessing the impact of the biopsy result on the diagnostic certainty using Bayes' theorem, and second, selecting a management plan based on this updated certainty and established clinical principles.\n\n**Step 1: Bayesian Update of Diagnostic Probability**\n\nWe are asked to compute the posterior probability of excoriation disorder given the finding of non-specific histology, denoted as $P(\\text{excoriation disorder} \\mid \\text{non-specific histology})$. We will use the odds form of Bayes' theorem. Let $D$ be the event that the patient has excoriation disorder, and let $T^+$ be the event of a positive test result, which is the \"non-specific ulceration\" on histology.\n\nThe given pretest probability is $P(D) = 0.70$.\nFirst, we calculate the prior odds of having excoriation disorder:\n$$ \\text{prior odds} = \\frac{P(D)}{1 - P(D)} = \\frac{0.70}{1 - 0.70} = \\frac{0.70}{0.30} = \\frac{7}{3} $$\n\nNext, we calculate the positive likelihood ratio ($LR^+$) for the test. We are given:\n-   Sensitivity: $P(T^+ \\mid D) = 0.80$\n-   Specificity: $P(T^- \\mid D^c) = 0.20$, where $D^c$ is the absence of excoriation disorder.\n\nThe $LR^+$ is defined as:\n$$ LR^+ = \\frac{\\text{sensitivity}}{1 - \\text{specificity}} $$\nThe term $1 - \\text{specificity}$ represents the false positive rate, which is $P(T^+ \\mid D^c)$.\n$$ 1 - \\text{specificity} = 1 - 0.20 = 0.80 $$\nNow, we can compute the $LR^+$:\n$$ LR^+ = \\frac{0.80}{0.80} = 1 $$\n\nA likelihood ratio of $1$ indicates that the test result is equally likely in patients with the disease as in those without it. Therefore, the test provides no information to discriminate between these two groups and does not change our assessment of the odds.\n\nNow, we compute the posterior odds:\n$$ \\text{posterior odds} = \\text{prior odds} \\times LR^+ = \\frac{7}{3} \\times 1 = \\frac{7}{3} $$\n\nFinally, we convert the posterior odds back to a probability. For odds equal to $\\frac{p}{1-p}$, the probability $p$ is given by $p = \\frac{\\text{odds}}{1 + \\text{odds}}$.\n$$ P(D \\mid T^+) = \\frac{\\frac{7}{3}}{1 + \\frac{7}{3}} = \\frac{\\frac{7}{3}}{\\frac{3}{3} + \\frac{7}{3}} = \\frac{\\frac{7}{3}}{\\frac{10}{3}} = \\frac{7}{10} = 0.70 $$\n\nThe posterior probability, $P(\\text{excoriation disorder} \\mid \\text{non-specific histology})$, is $0.70$. This is identical to the prior probability. The calculation confirms that the non-specific biopsy result, given its statistical properties, does not alter the diagnostic probability. The \"conflicting signal\" is resolved: the biopsy is not conflicting but rather uninformative for confirming the diagnosis, while being useful for ruling out other specific pathologies (e.g., bullous disease, vasculitis).\n\n**Step 2: Selection of Management Strategy**\n\nOur diagnostic confidence in excoriation disorder remains high ($70\\%$) and is strongly anchored in the DSM-5 criteria, which the patient is stated to meet. The biopsy has served its purpose by not revealing an alternative primary dermatologic disease. Therefore, the correct course of action is to initiate treatment for the established diagnosis of excoriation disorder.\n\n-   The first-line, evidence-based treatment for excoriation disorder is psychotherapy, specifically Cognitive Behavioral Therapy (CBT), often including a component called Habit Reversal Training (HRT).\n-   Comprehensive management also includes psychoeducation, stimulus control strategies, and simple, non-pharmacologic wound care to prevent secondary infection and promote healing.\n-   A collaborative care model involving both dermatology and mental health professionals is recognized as the best practice.\n\nNow we evaluate the given options based on these principles.\n\n**A. Initiate Cognitive Behavioral Therapy (CBT) with Habit Reversal Training (HRT), provide psychoeducation, stimulus control, and simple wound care; coordinate collaborative care with mental health; defer immunosuppression and antibiotics absent signs of infection.**\nThis option aligns perfectly with the evidence-based standard of care. It proposes the correct first-line psychotherapy (CBT/HRT), includes essential supportive measures, advocates for the ideal collaborative care model, and correctly advises against treatments for conditions that have been reasonably excluded.\n**Verdict: Correct.**\n\n**B. Escalate to systemic corticosteroids for presumed autoimmune blistering disease to reduce excoriations while arranging repeat biopsies.**\nThis is incorrect. The negative direct immunofluorescence (DIF) makes an autoimmune blistering disease very unlikely. Initiating systemic corticosteroids is not indicated and would expose the patient to unnecessary and significant risks. It ignores the definitive behavioral diagnosis.\n**Verdict: Incorrect.**\n\n**C. Perform repeat biopsies from the edge of new lesions and treat empirically with doxycycline; postpone any behavioral intervention until histology is definitive.**\nThis is incorrect. Histology is not a \"definitive\" test for excoriation disorder; the diagnosis is behavioral. The initial biopsy was non-specific, which is a common finding, and repeat biopsies are unlikely to be more helpful. Postponing behavioral therapy is a disservice to a patient with \"clinically significant distress.\"\n**Verdict: Incorrect.**\n\n**D. Start high-dose isotretinoin for presumed acne excoriée and avoid psychiatric referral to prevent reinforcement of picking behavior.**\nThis is incorrect on multiple grounds. There is no mention of underlying acne. More importantly, avoiding psychiatric referral is precisely the wrong approach for a primary psychiatric disorder. The notion that referral would \"reinforce\" the behavior is a harmful misconception.\n**Verdict: Incorrect.**\n\n**E. Initiate N-acetylcysteine (NAC) and a Selective Serotonin Reuptake Inhibitor (SSRI) without psychotherapy; treat excoriations with topical corticosteroids because pharmacotherapy alone has the strongest evidence base.**\nThis is incorrect. The claim that pharmacotherapy alone has the strongest evidence base is false; psychotherapy (CBT/HRT) is considered first-line. While NAC and SSRIs have a role, they are typically used as adjuncts or second-line options, not as a monotherapy replacement for psychotherapy.\n**Verdict: Incorrect.**\n\nThe only appropriate next step is to accept the robust clinical diagnosis of excoriation disorder, which was not undermined by the uninformative biopsy, and to initiate the standard-of-care, psychotherapy-based treatment regimen.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "After establishing a diagnosis, the focus shifts to evidence-based treatment. To make informed decisions, clinicians must be adept at interpreting the results of clinical trials. This practice problem provides a direct opportunity to translate the outcomes of a hypothetical randomized controlled trial into metrics with tangible clinical significance . By calculating the Absolute Risk Reduction ($ARR$) and the Number Needed to Treat ($NNT$), you will practice converting statistical probabilities into a clear assessment of an intervention's real-world impact, a fundamental skill for applying evidence-based medicine in psychodermatology.",
            "id": "4489407",
            "problem": "A randomized, double-blind, placebo-controlled clinical trial in psychodermatology enrolled adults with either trichotillomania or excoriation (skin-picking) disorder. The intervention arm received N-acetylcysteine (NAC), and the control arm received placebo. Response was defined a priori as achieving a clinically meaningful reduction on a validated disorder-specific severity scale at the end of the treatment period. The observed response probability in the NAC arm was $0.50$, and the observed response probability in the placebo arm was $0.30$. Using foundational definitions from evidence-based medicine for risk difference and number needed to treat (NNT), derive from first principles the absolute benefit attributable to NAC compared with placebo and the corresponding number needed to treat for one additional responder. Report the computed absolute risk reduction (ARR; here, the absolute benefit increase for a desirable outcome) and the NNT as pure numbers (no units). Do not use percentage notation in the final reported values. After computing, provide a brief qualitative interpretation of these quantities in terms of clinically tangible outcomes for this patient population within the trial time frame. No rounding is required; report exact values.",
            "solution": "The problem statement will first be validated for scientific soundness, clarity, and completeness.\n\n### Step 1: Extract Givens\n- **Trial Design**: Randomized, double-blind, placebo-controlled clinical trial.\n- **Patient Population**: Adults with either trichotillomania or excoriation disorder.\n- **Intervention Arm**: N-acetylcysteine (NAC).\n- **Control Arm**: Placebo.\n- **Outcome Definition**: Response is defined as achieving a clinically meaningful reduction on a validated disorder-specific severity scale. This is a desirable outcome.\n- **Observed Response Probability in Intervention Arm**: $P_T = 0.50$.\n- **Observed Response Probability in Control Arm**: $P_C = 0.30$.\n- **Required Calculations**: Absolute Risk Reduction (ARR, also termed absolute benefit increase) and Number Needed to Treat (NNT).\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientific Groundedness**: The problem is scientifically grounded. It describes a standard clinical trial methodology (randomized, double-blind, placebo-controlled) and uses established concepts from evidence-based medicine and epidemiology, such as response probability, absolute risk reduction, and number needed to treat. The context of psychodermatology, specifically trichotillomania and excoriation disorder, and the use of N-acetylcysteine as an intervention are consistent with existing clinical research.\n2.  **Well-Posedness**: The problem is well-posed. It provides all necessary data points (the response probabilities in the treatment and control arms) to calculate the requested metrics. The definitions for ARR and NNT are standard and unambiguous, leading to a unique and meaningful solution.\n3.  **Objectivity**: The problem is objective. It presents factual data from a hypothetical (but realistic) clinical trial without subjective language or bias.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is self-contained, scientifically sound, and well-posed. A solution will be derived from first principles.\n\n### Solution Derivation\n\nThe problem requires the calculation of two fundamental metrics in evidence-based medicine: the Absolute Risk Reduction (ARR) and the Number Needed to Treat (NNT).\n\nLet $P_T$ denote the probability of a positive outcome (response) in the treatment group (NAC).\nLet $P_C$ denote the probability of a positive outcome (response) in the control group (placebo).\n\nFrom the problem statement, we are given:\n$P_T = 0.50$\n$P_C = 0.30$\n\n**1. Absolute Risk Reduction (ARR)**\n\nThe term \"Absolute Risk Reduction\" is typically used when the outcome is adverse (e.g., death, complication). In this case, the outcome is desirable (response to treatment). Therefore, the more precise term is Absolute Benefit Increase (ABI). However, the problem explicitly states to compute ARR, clarifying that it represents the \"absolute benefit increase.\" This quantity measures the absolute difference in the rates of the favorable outcome between the treatment and control groups.\n\nThe formula is derived from the difference in outcome probabilities:\n$$\n\\text{ARR} = P_T - P_C\n$$\nSubstituting the given values:\n$$\n\\text{ARR} = 0.50 - 0.30 = 0.20\n$$\nThis value represents the absolute increase in the probability of a patient responding to treatment when given NAC compared to placebo.\n\n**2. Number Needed to Treat (NNT)**\n\nThe Number Needed to Treat (NNT) is a measure of the clinical effort required to achieve one additional positive outcome. It is defined as the reciprocal of the Absolute Risk Reduction (ARR). The derivation is straightforward: if an ARR of $0.20$ means that for every $100$ patients treated, we get $20$ extra positive outcomes, then the number of patients we need to treat to get $1$ extra positive outcome is $100/20$. Generalizing this, NNT is $1/\\text{ARR}$.\n\nThe formula is:\n$$\n\\text{NNT} = \\frac{1}{\\text{ARR}}\n$$\nUsing the calculated value for ARR:\n$$\n\\text{NNT} = \\frac{1}{0.20} = \\frac{1}{1/5} = 5\n$$\nThe NNT is a pure number, as it represents a number of patients.\n\n**3. Qualitative Interpretation**\n\n- **Absolute Risk Reduction (ARR)**: The calculated ARR of $0.20$ signifies that treatment with N-acetylcysteine results in an absolute increase of $20$ percentage points in the response rate compared to placebo. Phrased differently, for every $100$ patients treated with NAC, there will be $20$ additional responders who would not have responded had they been given placebo.\n\n- **Number Needed to Treat (NNT)**: The calculated NNT of $5$ provides a tangible measure of clinical impact. It means that, on average, it is necessary to treat $5$ patients with trichotillomania or excoriation disorder with NAC for the duration of the trial to achieve one additional clinically meaningful response that would not have occurred with placebo. This metric is highly useful for clinicians in weighing the benefits of a treatment against its costs and potential side effects.\n\nThe computed values are exact and do not require rounding.\nThe final answer reports the ARR and NNT in that order.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.20 & 5\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Trichotillomania and excoriation disorder are typically chronic, with courses that fluctuate between periods of control and relapse. Understanding and communicating this long-term trajectory is essential for effective patient counseling and management. This exercise introduces a powerful conceptual tool—a two-state Markov model—to formally describe this dynamic process . By modeling the transitions between remission and relapse, you will derive the long-run probability of a patient being in a state of relapse, providing a quantitative framework for understanding the chronicity of these disorders and the goals of maintenance therapy.",
            "id": "4489408",
            "problem": "In psychodermatology, symptom trajectories for body-focused repetitive behaviors such as trichotillomania and excoriation (skin picking) disorder often fluctuate between periods of symptom control and symptom recurrence. To capture this fluctuation abstractly in a scientifically tractable way, consider a time-homogeneous, discrete-time Markov model with two states: remission, denoted by $R$, and relapse, denoted by $r$. The model is constructed so that at each discrete time step a patient either remains in the same state or transitions to the other state according to fixed transition probabilities. Assume that for trichotillomania, the probability of transitioning from remission to relapse is $P(R \\to r) = 0.2$ and the probability of transitioning from relapse to remission is $P(r \\to R) = 0.4$. All remaining transition probabilities are determined by normalization of probabilities on outgoing transitions from each state. Under the standard assumptions of irreducibility and aperiodicity that guarantee convergence to a unique steady state for such a two-state model, derive the long-run (steady-state) probability of being in the relapse state $r$ for trichotillomania starting from the foundational definitions of a time-homogeneous Markov process and probability conservation. Express your final answer exactly as a fraction in simplest form with no units.",
            "solution": "The problem is validated as self-contained, scientifically grounded, and well-posed. It describes a standard two-state, discrete-time, time-homogeneous Markov chain, which is a valid and widely used mathematical model for studying dynamic systems with discrete states. The provided probabilities are consistent, and the assumptions of irreducibility and aperiodicity guarantee the existence of a unique steady-state distribution. We may therefore proceed with the derivation.\n\nLet the state space of the Markov process be $S = \\{R, r\\}$, where $R$ denotes the state of remission and $r$ denotes the state of relapse. Let $\\pi_R$ and $\\pi_r$ be the long-run, or steady-state, probabilities of being in state $R$ and state $r$, respectively. By the law of total probability, these probabilities must sum to unity, as the system must be in one of the two states at any given time.\n$$\n\\pi_R + \\pi_r = 1\n$$\nThis constitutes our first governing equation.\n\nThe problem provides the transition probabilities between the states. Let $p_{ij}$ denote the probability of transitioning from state $i$ to state $j$ in a single time step, where $i, j \\in \\{R, r\\}$. The given values are:\n$$\np_{Rr} = P(R \\to r) = 0.2\n$$\n$$\np_{rR} = P(r \\to R) = 0.4\n$$\nThe remaining transition probabilities, which correspond to the system remaining in its current state, are determined by the fact that the sum of probabilities of all outgoing transitions from any given state must be $1$.\nFor state $R$, the outgoing transitions are to $R$ or $r$. Thus:\n$$\np_{RR} + p_{Rr} = 1 \\implies p_{RR} = 1 - p_{Rr} = 1 - 0.2 = 0.8\n$$\nFor state $r$, the outgoing transitions are to $R$ or $r$. Thus:\n$$\np_{rR} + p_{rr} = 1 \\implies p_{rr} = 1 - p_{rR} = 1 - 0.4 = 0.6\n$$\n\nThe steady-state distribution $\\pi = (\\pi_R, \\pi_r)$ is defined as the probability distribution that remains unchanged over time. This means that if the system is in the steady state, the probability distribution at the next time step is identical to the current one. This condition of stationarity can be expressed as a balance equation for each state. For any given state, the total probabilistic flux into that state must equal the total probabilistic flux out of it.\n\nEquivalently, and more directly, we can state that the probability of being in a particular state at time $n+1$ (assuming steady state) is the sum of the probabilities of transitioning into it from all possible states at time $n$. For state $r$, this is expressed as:\n$$\n\\pi_r = \\pi_R \\cdot p_{Rr} + \\pi_r \\cdot p_{rr}\n$$\nSubstituting the value of $p_{rr} = 1 - p_{rR}$:\n$$\n\\pi_r = \\pi_R \\cdot p_{Rr} + \\pi_r \\cdot (1 - p_{rR})\n$$\nRearranging this equation:\n$$\n\\pi_r - \\pi_r \\cdot (1 - p_{rR}) = \\pi_R \\cdot p_{Rr}\n$$\n$$\n\\pi_r - \\pi_r + \\pi_r \\cdot p_{rR} = \\pi_R \\cdot p_{Rr}\n$$\n$$\n\\pi_r \\cdot p_{rR} = \\pi_R \\cdot p_{Rr}\n$$\nThis powerful result is the \"balance equation,\" which states that in the steady state, the probabilistic flow from state $R$ to state $r$ is exactly balanced by the flow from state $r$ to state $R$. This equation, along with the normalization condition, is sufficient to determine the unique steady-state probabilities.\n\nWe now have a system of two linear equations for the two unknowns, $\\pi_R$ and $\\pi_r$:\n1. $\\pi_R + \\pi_r = 1$\n2. $\\pi_r \\cdot p_{rR} = \\pi_R \\cdot p_{Rr}$\n\nSubstituting the given numerical values for the transition probabilities into the second equation:\n$$\n\\pi_r \\cdot (0.4) = \\pi_R \\cdot (0.2)\n$$\nDividing by $0.2$, we find a direct relationship between $\\pi_R$ and $\\pi_r$:\n$$\n2 \\pi_r = \\pi_R\n$$\nNow, we substitute this expression for $\\pi_R$ into the normalization equation (1):\n$$\n(2 \\pi_r) + \\pi_r = 1\n$$\n$$\n3 \\pi_r = 1\n$$\nSolving for $\\pi_r$, the steady-state probability of being in the relapse state, we get:\n$$\n\\pi_r = \\frac{1}{3}\n$$\nFor completeness, we can also find $\\pi_R$:\n$$\n\\pi_R = 2 \\pi_r = 2 \\left(\\frac{1}{3}\\right) = \\frac{2}{3}\n$$\nThese probabilities sum to unity, $\\frac{2}{3} + \\frac{1}{3} = 1$, confirming the consistency of our result. The problem requires the long-run probability of being in the relapse state, $r$, which is $\\pi_r$.",
            "answer": "$$\\boxed{\\frac{1}{3}}$$"
        }
    ]
}